Protein Kinase Inhibitors: all 15,766 studies that test it

Page 12 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
• Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingNCT06712173Phase 1
• Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABCNot yet recruitingNCT06711094Not applicable
• Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Not applicable
• Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
• HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid TumoursRecruitingNCT06708663Phase 1/2
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsRecruitingNCT06706076Phase 1/2
• A Phase 2 Study of HX301 in Patients with High-grade GilomaRecruitingNCT06703255Phase 1/2
• Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialRecruitingNCT06700798Phase 2
• Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCCNot yet recruitingNCT06699498Phase 2
• Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinRecruitingNCT06698965Phase 2
• A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIARecruitingNCT06698822Phase 2
• Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2
• Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer PatientsNot yet recruitingNCT06697990Phase 2
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerRecruitingNCT06696768Phase 1
• Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive TreatmentRecruitingNCT06696183Phase 2
• First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 2
• A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]RecruitingNCT06693284Early Phase 1
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Tofacitinib in Patients With Amyotrophic Lateral SclerosisNot yet recruitingNCT06689982Early Phase 1
• Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction PatientsRecruitingNCT06689566Not applicable
• JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
• Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence RiskRecruitingNCT06685289Phase 2
• Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingNCT06685276Phase 2
• Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
• Upadacitinib as a Novel Treatment for Refractory Eyelid DermatitisRecruitingNCT06684522Early Phase 1
• Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose ToleranceRecruitingNCT06684106Not applicable
• Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNot yet recruitingNCT06682884Phase 2
• A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)Not yet recruitingNCT06682767Phase 1/2
• Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host DiseaseRecruitingNCT06682169Phase 3
• Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
• Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingNCT06680050Phase 2
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerRecruitingNCT06678269Phase 1
• Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT06678230Phase 2
• Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06675123Phase 1
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsRecruitingNCT06674343Phase 3
• Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2
• Different Doses of Sirolimus for the Treatment of Cystic Lymphatic MalformationsRecruitingNCT06673290Phase 2/3
• A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNot yet recruitingNCT06672068Phase 2
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesRecruitingNCT06671483Phase 3
• Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2
• Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
• Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
• Study of ACR-2316 in Specific Advanced Solid TumorsRecruitingNCT06667141Phase 1/2
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06667076Phase 2
• Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPKRecruitingNCT06666348Phase 1/2
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• Drug-Drug Interaction (DDI) Study for TQB3616Not yet recruitingNCT06662773Phase 1
• YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic CancerNot yet recruitingNCT06662669Phase 1/2
• Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingNCT06661720Phase 3
• Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative ColitisRecruitingNCT06660693Phase 3
• Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic TherapyRecruitingNCT06660355Phase 2
• Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid TumorsRecruitingNCT06658353Phase 3
• RESTOR: PK/PD mTORi Inhibition in Older AdultsRecruitingNCT06658093Early Phase 1
• Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
• A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
• A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaNot yet recruitingNCT06656091Phase 3
• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT06655246Phase 1
• A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingNCT06654882Phase 3
• Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingNCT06654037Phase 1
• IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingNCT06654011Phase 2
• Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor CellsRecruitingNCT06653777Phase 2
• Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaRecruitingNCT06653517Phase 2
• High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKIRecruitingNCT06652048Phase 2
• Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingNCT06651970Phase 4
• Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast CancerEnrolling by invitationNCT06650748Phase 2
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
• Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNot yet recruitingNCT06648525Phase 2
• Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT06648096Phase 1/2
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
• Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
• High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
• TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal HypertensionRecruitingNCT06646198Phase 2
• Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06644313Phase 2
• Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06644183Phase 1/2
• Nintedanib Treatment in Unicentric Castleman DiseaseNot yet recruitingNCT06643091Phase 2
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisRecruitingNCT06643000Not applicable
• A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Phase 3
• Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingNCT06640166Phase 2
• Safety of HRX215 in Patients After Minor and Major Liver ResectionRecruitingNCT06638502Phase 1/2
• Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast CancerRecruitingNCT06637150Phase 3
• Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathyRecruitingNCT06634108Phase 1/2
• A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung CancerRecruitingNCT06631989Phase 1/2
• Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDRecruitingNCT06631287Phase 3
• A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)RecruitingNCT06630234Phase 1/2
• A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingNCT06630091Phase 2
• Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06629584Phase 2
• Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of SepsisNot yet recruitingNCT06626984Phase 1/2
• TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITISNot yet recruitingNCT06625450Phase 4
• TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate CapsuleNot yet recruitingNCT06621082Phase 2
• Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate CapsuleNot yet recruitingNCT06620354Phase 2
• A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)RecruitingNCT06619561Phase 2
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
• A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingNCT06615050Phase 3
• An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast CancerNot yet recruitingNCT06613373Phase 4
• Study of Oral PCLX-001 in R/R Acute Myeloid LeukemiaRecruitingNCT06613217Phase 1

← Protein Kinase Inhibitors overview